Cancer Therapy

Phase I Results with Onyx-015 Updated

Published in Cancer Weekly, July 28th, 1997

Onyx Pharmaceuticals, Richmond, California, updated the results from a Phase I human safety study of its Onyx-015 anticancer virus in patients with recurrent and refractory head and neck tumors.

The company also announced that it has initiated a Phase II efficacy trial with Onyx-015 in that same indication and is planning to start Phase II testing of the virus in combination with chemotherapy.

In a presentation made at the Montgomery Securities Healthcare Conference, held in New York, Hollings C. Renton, Onyx, said that treatment with Onyx-015 was well-tolerated by all of the 32 patients completing the trial, and investigators observed no...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-07-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry